Related Experiment Videos
[A phase I study of carboplatin].
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|May 1, 1987
Summary
This phase I study of carboplatin in solid tumors found thrombocytopenia and leukopenia to be dose-limiting toxicities. Recommended doses for phase II trials are 300mg/m2 for poor-risk and 400mg/m2 for good-risk patients.
Area of Science:
- Oncology
- Pharmacology
- Clinical Trials
Context:
- Carboplatin is a platinum-based chemotherapy agent used to treat various solid tumors.
- Phase I studies are crucial for determining the safety and optimal dosage of new or repurposed drugs.
Purpose:
- To evaluate the safety, tolerability, and dose-limiting toxicities of carboplatin administered on a single-dose schedule in patients with solid tumors.
- To establish recommended dosages for carboplatin in phase II clinical trials based on patient risk stratification.
Summary:
- A single-dose carboplatin escalation study (200-500mg/m2) was conducted in 18 patients with various solid tumors.
- Thrombocytopenia and leukopenia were identified as dose-limiting toxicities, with gastrointestinal toxicity being a major clinical concern and nephrotoxicity minimal.
- Pharmacokinetic data were collected from 11 patients to further understand drug behavior.
Impact:
- Identified optimal carboplatin doses for phase II trials: 300mg/m2 (q 4w) for poor-risk patients and 400mg/m2 (q 4w) for good-risk patients.
- Provides essential data for the safe and effective use of carboplatin in future clinical investigations and patient treatment.